ArticleJournal of molecular histology2026
TGF-β1 inhibits CXCL1/CXCR2 signaling pathway to alleviate neuropathic pain in a spinal nerve ligation rat model.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Neuropathic pain (NPP) is a chronic and refractory condition resulting from injury or disease of the nervous system. This study aims to elucidate the molecular mechanism by which TGF-β1 alleviates neuropathic pain through modulation of the CXCL1/CXCR2 signaling pathway. A rat model of neuropathic pain was established via spinal nerve ligation (SNL). Mechanical allodynia and thermal hyperalgesia were assessed using electronic von Frey filaments and the plantar test, respectively. Histopathological changes, cellular apoptosis, and levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in spinal cord tissues were evaluated using hematoxylin and eosin (H&E) staining, TUNEL assay, and enzyme-linked immunosorbent assay (ELISA). Bioinformatics analysis (based on the GSE24982 dataset), quantitative real-time PCR (qRT-PCR), Western blotting, immunofluorescence staining, and dual-luciferase reporter assays were employed to investigate the regulatory role of TGF-β1 in the CXCL1/CXCR2 pathway. The direct inhibitory effect of TGF-β1 on CXCL1 expression was confirmed using primary astrocyte cultures, while intrathecal administration of a CXCL1 neutralizing antibody or the CXCR2 antagonist SB225002 was used to assess the functional impact of pathway blockade. SNL induced significant mechanical allodynia and thermal hyperalgesia, accompanied by spinal cord tissue damage, increased neuronal apoptosis, and elevated levels of pro-inflammatory cytokines. Expression of CXCL1 and CXCR2 was markedly upregulated following SNL. Double-immunofluorescence staining and quantitative co-localization analysis showed that CXCL1 signals were associated with GFAP-positive regions, whereas CXCR2 signals were associated with NeuN-positive regions, suggesting possible involvement of the CXCL1/CXCR2 axis in glia-neuron signaling. In primary astrocytes, TGF-β1 treatment was associated with SMAD2/3 signaling and reduced CXCL1 promoter activity and expression. In vivo, TGF-β1 attenuated pain-related behaviors, apoptosis, and neuroinflammation, whereas CXCL1 administration partially reversed these protective effects. TGF-β1 attenuates SNL-induced neuropathic pain at least partly by suppressing CXCL1 expression and modulating a CXCL1/CXCR2 axis that may be involved in glia-neuron signaling.
Indexed as
Identifiers
42287551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.